Johnson & Johnson said that it is ready .to begin the delivery of the vaccine immediately.
The US federal regulator said it plans to quickly approve using a single-component COVID-19 vaccine developed by Johnson & Johnson. A decision could be made as early as Saturday.
Earlier on Friday, a Food and Drug Administration (FDA) advisory panel reviewed the vaccine’s test results. It is recommended for use in people aged 18 and older, as the benefits of using the vaccine outweigh the risks.
Unlike the two-dose vaccines developed by Pfizer and Moderna, the Johnson & Johnson vaccine has only one component. It can be stored in a regular refrigerator, so it will be easier to distribute.
The tests, which involved 44 thousand people, showed that the effectiveness of the Johnson & Johnson vaccine is 66%: in Pfizer and Moderna vaccines, this figure is approximately 95%. However, experts urge not to pay too much attention to this since the Pfizer and Moderna tests were conducted before the appearance of the Brazilian, South African, and British strains of coronavirus and the Johnson & Johnson tests – when these strains were widely distributed.
Johnson & Johnson said it is ready to start delivering the vaccine immediately after receiving approval for its use and that it can provide 20 million doses by the end of March.